Abstract
Of 320 patients with metastatic malignant non-seminomatous germ cell tumours of the testis (NSGCT) treated with chemotherapy, 266 (83%) are alive and well after a median follow-up of 39 months. Deaths from treatment-related causes occurred in 9 patients and were related to intensity of chemotherapy. Relapse after chemotherapy was rare except in presentations with large tumour volume and high serum marker concentrations and a strategy has been developed of risk-related choice of chemotherapy in order to reduce treatment toxicity in good prognosis sub-groups of patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / analysis
-
Bleomycin / administration & dosage
-
Cisplatin / administration & dosage
-
Etoposide / administration & dosage
-
Follow-Up Studies
-
Humans
-
Male
-
Prognosis
-
Teratoma / drug therapy*
-
Testicular Neoplasms / drug therapy*
-
Vinblastine / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Biomarkers, Tumor
-
Bleomycin
-
Vincristine
-
Vinblastine
-
Etoposide
-
Cisplatin
Supplementary concepts
-
BEP protocol
-
PVB protocol